Abbott Receives FDA Approval for XIENCE PRIME

Abbott announced yesterday that they have received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System to treat coronary artery disease. With the introduction of XIENCE PRIME in the U.S., Abbott, the worldwide leader in drug eluting stent technology, offers an expanded range of drug eluting stents

Continue Reading